Activation of oncogenes by mechanisms other than genetic aberrations such as mutations, translocations, or amplifications is largely undefined. Here we report a novel isoform of the anaplastic lymphoma kinase (ALK) that is expressed in 11% of melanomas and sporadically in other human cancer types, but not in normal tissues. The novel ALK transcript initiates from a de novo alternative transcription initiation (ATI) site in ALK intron 19, and was termed ALK ATI . In ALK ATI -expressing tumours, the ATI site is enriched for H3K4me3 and RNA polymerase II, chromatin marks characteristic of active transcription initiation sites 1 . ALK ATI is expressed from both ALK alleles, and no recurrent genetic aberrations are found at the ALK locus, indicating that the transcriptional activation is independent of genetic aberrations at the ALK locus. The ALK ATI transcript encodes three proteins with molecular weights of 61.1, 60.8 and 58.7 kilodaltons, consisting primarily of the intracellular tyrosine kinase domain. ALK ATI stimulates multiple oncogenic signalling pathways, drives growthfactor-independent cell proliferation in vitro, and promotes tumorigenesis in vivo in mouse models. ALK inhibitors can suppress the kinase activity of ALK ATI , suggesting that patients with ALK ATI -expressing tumours may benefit from ALK inhibitors. Our findings suggest a novel mechanism of oncogene activation in cancer through de novo alternative transcription initiation.
Activation of oncogenes by mechanisms other than genetic aberrations such as mutations, translocations, or amplifications is largely undefined. Here we report a novel isoform of the anaplastic lymphoma kinase (ALK) that is expressed in 11% of melanomas and sporadically in other human cancer types, but not in normal tissues. The novel ALK transcript initiates from a de novo alternative transcription initiation (ATI) site in ALK intron 19, and was termed ALK ATI . In ALK ATI -expressing tumours, the ATI site is enriched for H3K4me3 and RNA polymerase II, chromatin marks characteristic of active transcription initiation sites 1 . ALK ATI is expressed from both ALK alleles, and no recurrent genetic aberrations are found at the ALK locus, indicating that the transcriptional activation is independent of genetic aberrations at the ALK locus. The ALK ATI transcript encodes three proteins with molecular weights of 61.1, 60.8 and 58.7 kilodaltons, consisting primarily of the intracellular tyrosine kinase domain. ALK ATI stimulates multiple oncogenic signalling pathways, drives growthfactor-independent cell proliferation in vitro, and promotes tumorigenesis in vivo in mouse models. ALK inhibitors can suppress the kinase activity of ALK ATI , suggesting that patients with ALK ATI -expressing tumours may benefit from ALK inhibitors. Our findings suggest a novel mechanism of oncogene activation in cancer through de novo alternative transcription initiation.
To identify novel mechanisms of oncogene activation, we performed transcriptome analyses (RNA sequencing (RNA-seq)) of metastatic melanoma and thyroid carcinoma. We used an algorithm 2 to investigate the differential expression of exons and focused our analysis on receptor tyrosine kinases with high expression of the kinase domain. In two melanoma (MM-15, MM-74) and one anaplastic thyroid carcinoma (ATC-28) samples, we identified a novel ALK transcript, which contained the ALK exons 20-29 preceded by , 400 base pairs (bp) of intron 19, but not exons [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . The novel ALK transcript was distinct from wild-type ALK, which contains all exons, and from ALK translocations, which usually encompass exons 20-29 with little intronic expression due to preserved splice sites ( Fig. 1a and Extended Data Fig. 1a-c) . We confirmed the presence of the novel ALK transcript with a northern blot (Extended Data Fig. 2a, b) .
The RNA-seq profile of the novel ALK transcript suggested an alternative transcription initiation site in intron 19, and we termed the novel transcript ALK ATI . We performed 59-rapid amplification of cDNA ends (59-RACE) and mapped the ATI site to a 25 bp region in intron 19 ( Table 1 ). ChIP-seq and ChIP-qPCR showed that only ALK ATIexpressing tumours, but not controls, had significant enrichment of histone H3K4me3 and RNA polymerase II (RNApol II) at the ATI site, which are typical of active promoters 1 ( Fig. 1c and Extended Data Fig. 3a, b ). These data suggest that ALK ATI originates from a newly established bona fide ATI site associated with characteristic chromatin alterations.
To determine the prevalence of ALK ATI expression, we screened more than 5,000 samples from 15 different cancer types in the TCGA RNA-seq data set. ALK ATI was expressed in , 11% of melanoma and sporadically in other cancer types (Extended Data Table 1 ). We found no ALK ATI expression in more than 1,600 samples from 43 different normal tissues in the Genotype-Tissue Expression (GTEx) RNA-seq data set 3 , indicating that ALK ATI is primarily expressed in a subset of cancer. To accurately distinguish and quantify the expression of ALK ATI , wild-type ALK, and translocated ALK in clinical specimens, we developed a NanoString nCounter assay 4 with probes in ALK exons 1-19, intron 19, and exons 20-29, and identified additional ALK ATI -expressing tumours derived from formalin-fixed paraffinembedded clinical specimens (Fig. 1d) .
To determine whether somatic genomic aberrations at the ALK locus contribute to the establishment of the de novo ATI site, we performed comprehensive genetic analyses including interphase fluorescence in situ hybridization (FISH), array comparative genomic hybridization (aCGH), whole-genome sequencing, and ultra-deep sequencing of the ALK locus, but found no genomic aberrations that could account for the de novo expression of ALK ATI (Extended Data Figs 4a-d and 5a-c, and Supplementary Tables 2-4). Reasoning that local genomic aberrations are usually cis-acting and only alter the expression of the affected allele 5 , we analysed the single nucleotide variants (SNVs) in the DNA-, RNA-, and ChIP-seq data. In all three data sets, we found similar allelic SNV frequencies, indicating that H3K4me3 decorates both ALK alleles and that both ALK alleles are actively transcribed (Fig. 1e) . These data suggest that the transcriptional activation of ALK ATI is independent of genomic aberrations at the ALK locus, and that alteration of trans-acting elements, such as transcription factors or chromatin modifiers, may contribute to ALK ATI expression.
The ATI region contains transposable elements, including a long terminal repeat (LTR) in ALK intron 19 and a long interspersed nuclear element (LINE) in intron 18, both of which can regulate transcription 6 (Extended Data Fig. 6a ). To evaluate whether CpG methylation of these elements might be associated with ALK ATI expression, we performed bisulfite sequencing. Compared to the controls, the ALK ATI -expressing samples showed lower CpG methylation in regions flanking the ATI site, including the LINE (Extended Data Fig. 6b-d) . The LTR contained only few CpG sites with low methylation levels in all samples. As expected, we found H3K27ac, a histone mark characteristic of active promoters and enhancers, enriched at the ATI site of ALK ATI -expressing tumour samples. Surprisingly, H3K27ac was also enriched in ALK ATI -negative melanoma samples, but not in the control lung cancer cell lines or the 17 non-melanoma cell lines analysed by the ENCODE consortium 7 (Extended Data Fig. 6e, f) . By integrating ChIP, DNase I hypersensitivity, and 59-RACE data, we defined the proximal cis-regulatory region on chromosome 2 as chr2:29,445,000-29,447,100 and computationally determined the potential transcription factor binding motifs 8 (Supplementary Table 5 ). To test whether the LTR could function as a promoter, we used a luciferase reporter assay and found that, in contrast to lung cancer cell lines, melanoma cell lines showed low but consistent luciferase activity (Extended Data Fig. 6g ). These data suggest that melanomas with H3K27ac enrichment at the ATI site might be primed to express ALK ATI . The ALK ATI transcript has three predicted in-frame start codons (ATGs), resulting in proteins with molecular weights of 61.1, 60.8, and 58.7 kilodaltons (kDa). All three proteins maintain the intracellular tyrosine kinase domain, but lack the extracellular and transmembrane domains of wild-type ALK (Fig. 2a) . Immunoblots of two neuroblastoma cell lines (SK-N-BE2, SK-N-DZ) expressing wild-type ALK and two lung cancer cell lines (H3122 and H2228) expressing two distinct variants of the EML4-ALK gene fusion showed bands at the expected sizes. ALK ATI -expressing tumours revealed a double band at , 60 kDa, suggesting that ALK ATI is translated from more than one start codon (Fig. 2b) . To confirm our prediction, we mutated the three start codons individually or in combination, and expressed them in 293T cells. Immunoblots revealed that each mutated form of ALK ATI no longer produced the corresponding protein band, indicating that all three start codons in ALK ATI are functional and give rise to three distinct proteins (Fig. 2c) .
ALK ATI proteins were phosphorylated in tumours with endogenous ALK ATI expression and in cells with exogenous ALK ATI expression (Fig. 2b, c) , indicating that ALK ATI is active. ALK activity was confirmed by an in vitro kinase assay (Extended Data Fig. 7a) . A kinasedead ALK ATI (ALK ATI-KD ), in which a lysine in the ATP-binding site of the kinase domain was replaced by a methionine 9 , was not phosphorylated or active. Reasoning that ALK ATI may auto-activate by forming homodimers similar to other receptor tyrosine kinases 10 , we tested the ability of self-interaction using co-immunoprecipitation with V5-and HA-tagged ALK ATI proteins. The V5-ALK ATI readily co-immunoprecipitated with the HA-ALK ATI and vice versa, indicating that ALK ATI can self-interact, resulting in auto-phosphorylation and kinase activity (Fig. 2d) . Using immunofluorescence, we detected ALK ATI in both the nucleus and the cytoplasm, whereas ALK with the ) and EML4-ALK were found mainly in the cytoplasm and/or at the cell membrane (Fig. 2e) . ALK immunohistochemistry in clinical samples confirmed the nuclear and cytoplasmic localization of ALK ATI , suggesting that detection of nuclear ALK expression by immunohistochemistry could be used as a simple biomarker to identify ALK ATI -expressing tumours ( Fig. 2f and Extended Data Fig. 7b) .
To establish the functional consequences of ALK ATI expression, we stably transduced Ba/F3, NIH-3T3 and melan-a cells with ALK , EML4-ALK, and wild type). In interleukin 3 (IL-3)-dependent Ba/F3 cells, expression of ALK ATI and the positive controls, but not the negative controls, led to IL-3-independent proliferation (Fig. 3a) . We confirmed that ALK ATI was expressed at similar levels in the transformed ALK ATI -Ba/F3 cells to those in human tumours, and that all ALK isoforms were phosphorylated when expressed at levels required for IL-3-independent growth (Fig. 3b) . In competition assays, only Ba/F3 cells expressing green fluorescent protein (GFP) co-expressed from the ALK expression vectors were growing under IL-3-independent growth conditions, 
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indicating that the Ba/F3 cell transformation was driven by expression of the ALK variants (Extended Data Fig. 7c ). Consistently, ALK ATI -expressing NIH-3T3 and melan-a cells efficiently induced tumour growth in mice with severe combined immunodeficiency (SCID) (Fig. 3c and Extended Data Fig. 7d-f ).
All cells expressing ALK variants (ALK ATI , ALK
F1174L
, EML4-ALK, and wild-type ALK) were able to establish growth-factor-independent proliferation and tumorigenesis with similar growth rates once the tumours were established. The observed oncogenic capacity of wildtype ALK is consistent with previous reports that high endogenous expression or genomic amplification of ALK drives oncogenesis and confers sensitivity to ALK inhibitors in neuroblastomas [11] [12] [13] [14] [15] [16] . To explore the functional consequences of ALK ATI expression further, we stably transduced NIH-3T3 cells with either a low or high titre of ALK ATI , resulting in cells expressing ALK ATI either at low or at high levels. We found that a further increase in ALK ATI expression levels did not accelerate tumour graft establishment and growth, indicating that ALK ATI can drive tumorigenesis once a threshold of expression is reached (Extended Data Fig. 7g-i) .
To examine the therapeutic responses to pharmacological ALK inhibition, we treated Ba/F3 cells stably expressing various ALK isoforms with three different ALK inhibitors (crizotinib, ceritinib, and TAE-684). All three ALK inhibitors effectively inhibited IL-3-independent growth of the transformed Ba/F3 cells, whereas they had no effect on growth in the presence of IL-3 ( Fig. 4a and Extended Data Fig. 8a, b) . Crizotinib inhibited ALK ATI phosphorylation and downstream signalling in a concentration-dependent manner, further corroborating that ALK ATI is activated through auto-phosphorylation ( Fig. 4b and Extended Data Fig. 8c-e) . Crizotinib treatment induced regression of ALK ATI -driven NIH-3T3 tumours in vivo, and immunohistochemistry of explanted tumours confirmed reduced cell proliferation, increased apoptosis, and inhibition of several oncogenic signalling pathways (Fig. 4c-e and Extended Data Fig. 9a-f ). On the basis of our pre-clinical data, we identified a patient with ALK ATI -expressing metastatic melanoma (Fig. 4f, g ). A clinical sequencing assay 17 , which evaluates 341 cancer-related genes for genomic aberrations, and FISH to assess ALK rearrangements and MET amplifications, revealed deletions of CDKN2A and PTEN (Extended Data Fig. 9g-i) . The patient had previously progressed on a combination of ipilimumab and nivolumab immunotherapy in a clinical trial, followed by palliative radiation and dacarbazine chemotherapy. Subsequent treatment with crizotinib resulted in marked symptomatic improvement and tumour shrinkage within 6 weeks of therapy (Fig. 4h) .
Taken together, we have identified a novel ALK transcript, ALK ATI , which arises independently of genomic aberrations at the ALK locus through alternative transcription initiation. ALK ATI -driven tumours are sensitive to ALK inhibitors, suggesting that patients harbouring such tumours may benefit from ALK inhibitor therapy. Importantly, we have discovered alternative transcription initiation as a novel mechanism for oncogene activation. Additional oncogenes may be activated via similar mechanisms in other human malignancies, and their identification may provide new insights into oncogenesis and opportunities for therapeutic intervention.
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METHODS
No statistical methods were used to predetermine sample size. Human tumour samples. The study was approved by the Institutional Review Boards and Ethics Committees of Memorial Sloan Kettering Cancer Center, New York and informed consent was obtained from all subjects (#12-245 and #00-144). Representative portions of excised tumours were snap-frozen in liquid nitrogen, or fixed in 4% neutral buffered formalin, embedded in paraffin, and processed using routine histological methods and stained with haematoxylin and eosin. RNA sequencing. Total RNA was extracted from fresh-frozen tissue sections (17 metastatic melanomas and 6 thyroid carcinomas) using an RNeasy Mini Kit (Qiagen). The isolated RNA was processed using the TruSeq RNA sample Prep kit (Illumina) according to the manufacturer's protocol. The libraries were sequenced on an Illumina HiSeq 2500 platform with 50, 75, or 100 bp pairedend reads to obtain on average 40,000,000-100,000,000 reads per sample. Sequencing data was mapped to hg19, and analysed using publicly available software packages: SAMtools Screening for aberrantly expressed kinases. For initial screening of RNA-seq data, candidate receptor tyrosine kinase (RTK) genes were defined by Gene Ontology annotation GO:0004714 as found in AmiGO 22 . DEXSeq 2 was used to calculate exon level counts using RTK Ensembl Gene IDs. For each gene the ratio of reads in the first half of the gene to the second half was calculated. ALK was identified as the top hit. Analysis of public data sets. RNA-seq data were downloaded from the Broad Institute GTEx Genotype-Tissue Expression Portal (http://www.broadinstitute.org/gtex/). Level 3 TCGA data was downloaded from the Broad Institute TCGA GDAC Firehose (http://gdac.broadinstitute.org/) 2013_09_23 run using exon_quantification data from illuminahiseq_rnaseqv2__unc_udu. ALK ATI candidates were identified as samples with an ALK expression level of RSEM $ 100, $ 500 total reads across all ALK exons, and $ 10-fold greater average expression in exons 20-29 compared to exons 1-19. To confirm ALK ATI expression, candidates were manually examined in IGV 21 . ENCODE ChIP-seq data for H3K27ac, mapped to hg19 and converted to bigwig track format, was downloaded from http://genome.ucsc.edu/ENCODE/dataMatrix/encodeChipMatrixHuman.html. Promoter/motif analysis. The proximal cis-regulatory region, chr2:29,445,000-29,447,100, was scanned for transcription factor motifs using FIMO 8 with default parameters against the known vertebrate transcription factor motifs in the JASPAR database 23 . 59-rapid amplification of cDNA ends (59-RACE). We used two independent 59-RACE techniques and three ALK ATI -expressing tumours (MM-15, MM-74, and ATC-28) to map the ATI site and the 59-end of the ALK ATI transcript. We applied a tobacco-acid-pyrophosphatase 59-RACE technique according to the manufacturer's protocol (Epicentre) using the following primers: 59-TCATACAC ATACGATTTAGGTGACACTATAGAGCGGCCGCCTGCAGGAAA-39; 59-CAGGTCACTGATGGAGGAGGTCTTGCCAGCAAAGCA-39. RACE products were sequenced on an Illumina MiSeq System with a 150 bp paired-end protocol according to the manufacturer's instructions. The sequencing reads were mapped to hg19 using BWA and visualized using IGV 21 . We confirmed the continuous transcription starting in ALK intron 19 with an independent oligonucleotide-based 59-RACE kit (Clontech) according to the manufacturer's protocol using the primers 59-CTAATACGACTCACTATAGGGC-39, 59-ACACCTGGCC TTCATACACCTCC-39. We cloned the RACE cDNA products into plasmids (Invitrogen) and analysed them with Sanger sequencing. Two lung cancer cell lines (H3122 and H2228) with EML4-ALK translocations were used as controls. Chromatin immunoprecipitation sequencing (ChIP-seq) and ChIP-qPCR. Chromatin was isolated from human tumour tissue and cell lines. Fresh-frozen human tumour tissue (MM-15, MM-74, and ATC-28) was sectioned with a microtome and cross-linked in 1% paraformaldehyde for 15 min. The cross-linked tissue samples were quenched in 125 mM glycine, washed in PBS, re-suspended in lysis buffer, ground in a Tenbroeck-style tissue grinder, and sonicated. Chromatin isolation from cell lines and immunoprecipitation was performed as previously described 24 . Solubilized chromatin was immunoprecipitated with antibodies against H3K4me3, H3K27ac, and RNApol II (all Active Motif). Sequencing was performed on an Illumina HiSeq 2500 with 51 bp single reads. Reads were aligned to hg19 using Bowtie within the Illumina Analysis Pipeline. Peak calling was performed using MACS 1.4 comparing immunoprecipitated chromatin with input chromatin 25 . ChIP-qPCR was performed on a ViiA 7 Real Time PCR System (Life Technologies) using Power SYBR Master Mix (Life Technology) with 3 technical replicates and 5 independent primers pairs, which are specified in Supplementary Table 6 . Ultra-deep targeted sequencing of the entire ALK locus and MSK-IMPACT. Targeted sequencing of the entire ALK locus was performed using custom hybridization capture probes tiling hg19 chr2:29,400,000-30,300,000 (Roche/ NimbleGen's SeqCap EZ). This region encompassed the entire genomic footprint of ALK and , 150 kb of upstream sequence. After the genomic DNA was fragmented (E220, Covaris), we prepared barcoded sequence libraries (New England Biolabs, Kapa Biosystems) and performed hybridization capture on barcoded pools. Using 250 ng of genomic DNA, we constructed libraries from 7 separate samples: 2 melanomas (MM-15 and MM-74), 1 anaplastic thyroid carcinoma (ATC-28), 2 lung cancer cell lines (H3122 and H2228) with EML4-ALK translocations, 1 melanoma cell line (SKMEL-28), and 1 control pool of 10 'normal' blood samples. Libraries were pooled at equimolar concentrations (100 ng per library) and used in the capture reaction as previously described 26 . To prevent off-target hybridization, we added a pool of spike-in blocker oligonucleotides complementary to the full sequences of all barcoded adaptors. The captured libraries were sequenced on an Illumina HiSeq 2500 to generate 75 bp paired-end reads. Sequence data were de-multiplexed using CASAVA, and aligned to hg19 using BWA 27 . Local realignment and quality score recalibration were performed using the Genome Analysis Toolkit (GATK) according to GATK best practices 28 . We achieved mean unique target sequence coverage of 1,778 3 per sample (range: 1,293-2,188 3). Sequence data were analysed to identify single nucleotide variants, small insertions/deletions (indels), and structural rearrangements. Single nucleotide variants were called using muTect 29 and were compared to the negative control pool (pooled 'normal' blood samples). Variants were retained if the variant allele frequency in the tumour was . 5 times than in the negative control and the frequency in the negative control was , 0.02. Validated SNPs in the dbSNP database were filtered out. Indels were called using the SomaticIndelDetector tool in GATK 28 and were retained if the tumour harboured . 3 supporting reads and the frequency in the negative control was , 0.02. DELLY was used to search for structural rearrangements 30 . Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) was performed as described previously 17 . Bisulfite sequencing of the entire ALK locus. We performed custom capture of the entire ALK locus using custom hybridization capture probes tiling the entire genomic footprint of ALK (900 kb, chr2:29,400,000-30,300,000) followed by bisulfite sequencing. After fragmentation (E220, Covaris) of 3 mg genomic DNA of each sample (MM-15, ATC-28, H3122, and SKMEL-28), libraries were prepared with the KAPA Hyper Prep Kit (Kapa Biosystems) without PCR amplification to preserve the methylation status. Of each barcoded library, 1 mg was pooled at equimolar concentrations and captured according to the manufacturer's protocol (Roche/NimbleGen's SeqCap EZ). After washing the Dynabeads M-270 (Life Technologies), the non-biotinylated tumour/cell line DNA was dissociated from the biotinylated capture beads with 0.5 M NaOH. The single-stranded eluted DNA was used for bisulfite conversion using the EZ DNA Methylation-Gold Kit (Zymo Research) according to the manufacturer's protocol, except for the 98 uC denaturation step. After bisulfite conversion, we used the KAPA HiFi Uracil PCR polymerase (Kapa Biosystems) to amplify the library, purified the reaction with Agencourt AMPure XP beads (A63881, Beckman Coulter), and sequenced the library on an Illumina MiSeq with a 150 bp paired-end protocol according to the manufacturer's instructions. Sequence data were aligned to hg19 and analysed using Bismark 31 . We compared the methylation level at CpG sites across all samples; no methylation was detected in the CHG and CHH contexts. Methylation was first computed as the number of methylated CpG reads vs the number of total reads covering each CpG site (sites with , 10 reads were excluded). A sliding window was used to determine the mean methylation level for every 250 bp region (with at least three CpGs) near the ALK promoter region (chr2:29,444,000-29,452,000). Differential methylation was evaluated using a Mann-Whitney test. Whole-genome sequencing. Whole-genome sequencing was performed at the New York Genome Center. Briefly, genomic DNA libraries were prepared from MM-15 and ATC-28 (no matched normal DNA was available) using the Illumina PCR-free kit. Libraries were sequenced on an Illumina HiSeq 2500 using the 100 bp paired-end whole-genome sequencing protocol. Sequence reads were mapped using BWA 27 and processed using GATK 28 . Genome-wide analyses of mutations (HaplotypeCaller 28 ), copy number alterations (FREEC) 32 , and structural variations (CREST) 33 were performed. Mutations were annotated with the Ensembl Variant Effect Predictor 34 and filtered to remove common polymorphisms. Non-synonymous mutations along with copy number alterations and structural variations were visualized using Circos 35 .
Allelic frequencies SNVs at the ALK locus. DNA-seq, RNA-seq, and ChIP-seq (H3K4me3) data were displayed in the Integrative Genomics Viewer and the allelic frequencies were compared for each single nucleotide variant (SNV). Array CGH. Genome-wide analysis of DNA copy number changes was conducted using an oligonucleotide SurePrint G3 Human CGH Microarray (Agilent) containing 1,000,000 probes. Slides were scanned using a microarray scanner G2505B (Agilent) and analysed using Genomic Workbench (Agilent).
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Interphase fluorescence in situ hybridization (FISH). ALK break-apart probes and locus-specific probes for MET and for centromere 7 were purchased from Abbott. The probes were hybridized on 5-mm-thick tissue sections and the number and localization of the hybridization signals was assessed in a minimum of 100 interphase nuclei with well-delineated contours. Northern blots. Total RNA was extracted from fresh-frozen tissue or cell lines using Qiagen's RNeasy Mini Kit (Qiagen). Up to 10 mg RNA was used for running formaldehyde-based northern blot analysis according to the manufacturer's protocol using the RNA Ambion NorthernMax Kit (Ambion). After hybridization with a 32 P-labelled probe, consisting of ALK exon 20-29, the membrane was washed and visualized. NanoString. Details of the nCounter Analysis System (NanoString Technologies) were reported previously 36 . In brief, two sequence-specific probes were constructed for ALK exons 1-19, intron 19, and exons 20-29, respectively. Four control genes (RPS13, RPL27, RPS20, and ACTB) were used for normalization. The probes were complementary to a 100 bp region of the target mRNA and are listed in Supplementary Table 7 . 100 ng of total RNA from each sample was hybridized, the raw data were normalized to the standard curve generated via the nCounter system, and the average value of the two probes in each target region (exons 1-19, intron 19, exons 20-29) was printed in bar charts using GraphPad Prism software 6.0. NanoString experiments were independently performed at least twice with appropriate positive and negative controls, and a representative experiment is shown. 37 and were maintained in RPMI supplemented with 200 nM 12-Otetradecanoylphorbol-13-acetate (TPA; Cell Signaling). For retrovirus production, 293T cells were purchased (Clontech) and cultured in DMEM. All cell culture media contained 10% FBS, L-glutamine (2 mM), penicillin (100 U ml 21 ), and streptomycin (100 mg ml
21
). All cells were cultured at 37 uC in 5% CO 2 and were biochemically tested negative for mycoplasma contamination every 4-8 weeks (Lonza). After receiving the cell lines from the indicated sources, the cell lines were not further authenticated, but showed the expected genomic aberrations, such as EML4-ALK translocations. The genomic aberrations have been validated by various methods, including RNA-seq or northern blot. Plasmids. For the ALK ATI vector, RNA from MM-15 was reverse-transcribed with anchored oligo(dT) primers into cDNA (Roche), PCR amplified with ALK the primers 59-CACCATCCCATCTCCAGTCTGCTTC-39, 59-AGAGAAGTGA GTGTGCGACC-39, and cloned into a pENTR vector (Life Technologies). The full-length ALK plasmid (HsCD00079531) was purchased from the DF/HCC DNA Resource Core (http://plasmid.med.harvard.edu) and EML4-ALKv1 was synthesized at GeneArt (Life Technologies). Site-directed mutagenesis was performed using QuikChange (Agilent): for kinase-dead ALK ATI (ALK ATI-KD ), we mutated the lysine in the ATP-binding site of the kinase domain to methionine (p.K1150M referring to wild-type ALK) in ALK ATI , and for ALK F1174L a p.F1174L mutation was introduced into wild-type ALK. Plasmids were sub-cloned into pMIG-w backbones 38 (http://www.addgene.org), resulting in MSCV-ALK variant -IRES-GFP constructs, which were confirmed by digestion and sequencing. To confirm the start codons, we mutated the three start codons from ATG to AAG individually or in combination as indicated. For co-immunoprecipitation, ALK ATI was subcloned into pcDNA3.1/nV5-Dest (Life Technologies) and MSCV-N-HA-FLAG-Dest (Addgene). For bioluminescence imaging, we used a triple modality retroviral reporter plasmid (red fluorescent protein (RFP)-thymidine-kinaseluciferase) 39 . Stable gene expression. Retrovirus was produced in 293T cells by standard methods using ecotropic or amphotropic packaging vectors and XtremeGene 9 (Roche). We harvested the virus-containing supernatant 48, 64 and 72 h after transfection. The supernatant was pooled, filtered through a 0.45 mm PVDF membrane, and used for transduction in the presence of polybrene (8 mg ml
). Stable eGFP-or RFP-expressing cells were sorted with a FACSAria II (BD Biosciences).
Co-immunoprecipitation. V5-ALK
ATI and HA-ALK ATI was transiently transfected into 293T cells using XtremeGene 9 (Roche), and after 24 h, cells were lysed in 10 mM Tris-HCl (pH 7.5), 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, and proteinase/phosphatase inhibitors. After incubation and centrifugation, 100 ml supernatant was used as input, and 300 ml for immunoprecipitation using the following antibodies: 2 mg of anti-V5 antibody (Thermo Scientific), 10 ml of EZview Red anti-HA Affinity Gel (Sigma), 2 mg of anti-mouse IgG (Santa Cruz). We used 20 ml of Protein A/G UltraLink Resin (Thermo Scientific) for immunoprecipitation. The immunoprecipitated material was eluted in 4 3 SDS loading buffer for immunoblotting. Co-immunoprecipitation was independently performed twice and a representative immunoblot is shown in Fig. 2d . In vitro kinase assay. Stably transduced NIH-3T3 cells were grown in a 15 cm dish, washed with PBS, and lysed in 20 mM Tris (pH 8.0), 1% NP-40, 125 mM NaCl, 2.5 mM MgCl 2 , and 1 mM EDTA with proteinase/phosphatase inhibitor. Lysates were incubated on ice, centrifuged, pre-cleared with 25 ml Protein A/G UltraLink Resin (Thermo Scientific) for 30 min at 4 uC under rotation, and immunoprecipitated with 10 ml ALK (D5F3) XP Rabbit monoclonal antibody and 25 ml Protein A/G UltraLink Resin. After rotation for 120 min at 4 uC, the immunoprecipitated material was washed and used according to the instructions of Universal Tyrosine Kinase Assay Kit (Clontech). After the enzymatic reaction, the immunoprecipitated material was mixed with 4 3 SDS loading buffer for immunoblotting. In vitro kinase assays were performed in quadruplicates, independently repeated three times, and a representative experiment is shown. Immunohistochemistry. Immunohistochemistry was performed on archival formalin-fixed paraffin-embedded tumour specimens using a standard multimer/diaminobenzidine (DAB) detection protocol on a Discovery Ultra system (Roche/ Ventana) with appropriate negative and positive controls. The following antibodies (Cell Signaling Technology) were diluted in SignalStain antibody diluent (Cell Signaling Technology) as indicated: ALK 1:250; phospho-Akt (Ser473) 1:50; phospho-STAT3 (Tyr705) 1:400; phospho-S6 (Ser235/236) 1:400; phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 1:400; cleaved caspase-3 (Asp175) 1:400. The anti-Ki67 antibody was diluted 1:600 (Abcam). Immunofluorescence. Stably transduced NIH-3T3 cells were grown on coverslips, fixed in 4% formaldehyde, washed in PBS, and incubated in blocking solution (5% goat serum and 0.1% Triton X-100 in PBS). After blocking, cells were incubated with an ALK monoclonal antibody (Cell Signaling Technology) diluted 1:1,000 in blocking buffer overnight at 4 uC. After washing the cells with 0.05% Tween 20 and PBS, cells were incubated with a secondary antibody (Life Technologies) diluted 1:500 in blocking buffer for 2 h at room temperature. After washing in PBS, slides were mounted with Prolong Gold Antifade Reagent with DAPI (Cell Signaling Technology) and imaged with a Leica TCS SP5 II confocal microscope. Immunofluorescence was independently performed twice and a representative experiment is shown in Fig. 2e . Immunoblot. Cell lysates were prepared in RIPA buffer supplemented with proteinase/phosphatase inhibitor. Proteins were resolved in NuPAGE Novex 4-12% Bis-Tris Protein Gels (Life Technologies) and transferred electrophoretically onto a nitrocellulose 0.45 mm membrane (BioRad). Membranes were blocked for 1 h at room temperature in Odyssey Blocking Buffer (LI-COR) and were incubated overnight at 4 uC with the primary antibodies diluted at 1:1,000 in 50% Odyssey Blocking Buffer in PBS plus 0.1% Tween 20. The following primary antibodies were used (all from Cell Signaling Technologies unless stated otherwise): anti-atubulin (Sigma-Aldrich), anti-V5 (Thermo Scientific), anti-HA3F10 (Roche), phospho-ALK (Tyr1604), ALK, phospho-Akt (Ser473), Akt, phospho-STAT3 (Tyr705), STAT3, phospho-S6 (Ser235/236), S6, phospho-p44/42 MAPK (Erk1/ 2) (Thr202/Tyr204), p44/42 MAPK (Erk1/2), phospho-MEK1/2 (Ser221), MEK1/ 2, phospho-PRAS40 (Thr246), PRAS40 (D23C7), phospho-SHP-2 (Tyr580), SHP-2. After 4 washes of 5 min in PBS-T, membranes were incubated with secondary antibodies (IRDye 800CW goat anti-Rabbit, 1:20,000, LI-COR; IRDye 680RD goat anti-mouse, 1:20,000, LI-COR) in 50% Odyssey Blocking Buffer in PBS plus 0.1% Tween 20 for 45 min at room temperature. After 4 washes in PBS-T and a final wash with PBS, membranes were scanned with a LI-COR Odyssey CLx scanner and adjusted using LI-COR Image Studio. Immunoblots were independently performed at least twice and a representative experiment is shown in Figs 2b-d 3b, 4b and Extended Data Figs 7a, 7d, 7f, 7h, 8c-e. Luciferase reporter assay. The long terminal repeat in ALK intron 19 at the ATI site (LTR16B2, chr2:29,446,649-29,447,062; 414 bp) was amplified using genomic DNA from patient MM-15 and 59-GTCCTCATGGCTCAGCTTGT-39 and 59-AGCACTACACAGGCCACTTC-39 primers. The PCR product (chr2:29,446, 444-29,447,174; 731 bp) was cloned into pGL4.14-firefly luciferase vector (Promega). To determine the promoter activity of LTR16B2, 10 5 cells were transfected in triplicates with 500 ng pGL4.14-LTR16B2 or vector alone; as internal control, 200 ng pRL-TK-Renilla luciferase reporter vector (Promega) was LETTER RESEARCH co-transfected. Luciferase activity was measured using Dual-Glo Luciferase Assay System (Promega) 48 h after transfection. Promoter activity was calculated by normalizing firefly luciferase activity to the control Renilla luciferase activity and compared between pGL4.14-LTR16B2 and vector alone. The luciferase reporter assays were independently performed three times, the results were combined, and the mean 6 s.d. is shown in Extended Data Fig. 6g . Flow cytometry and fluorescence-activated cell sorting (FACS). Flow cytometry analysis for in vitro transformation assays with Ba/F3 cells was performed on an LSRFortessa (BD Biosciences) at day 0 and day 14 after IL-3 withdrawal. GFPor RFP-positive cells were sorted using the FITC (blue laser) or PE (yellow laser) channel, respectively, on a FACSAria II configured with 5 lasers (BD Biosciences). In vitro transformation and drug treatment assays. Stably transduced Ba/F3 cells were cultured in RPMI medium supplemented with IL-3 (1 ng ml
21
). For the cell proliferation assay, Ba/F3 cells were transferred into IL-3 depleted RPMI medium, and cell growth was quantified in quadruplicates every 2-4 days by a luminescence assay (Promega). For cell viability assays and ALK inhibitor-doseresponse curves, 2,000 Ba/F3 cells were plated in triplicates in 96-well plates with increasing concentrations of the ALK inhibitors crizotinib (LC laboratories), TAE-684 (ChemieTek), or ceritinib (ChemieTek) as indicated. All drugs were re-suspended in DMSO. The cell viability was assessed after 72 h by a luminescence assay (Promega). Results were normalized to cell growth in medium containing an equivalent concentration of DMSO. The inhibition curve was determined with GraphPad Prism 6.0 software using the 'log(inhibitor) vs response -variable slope' nonlinear regression model. For immunoblots, 10 million Ba/F3 cells were harvested after 2 h treatment with crizotinib, washed in ice-cold PBS, and lysed in RIPA buffer. All assays were independently performed at least twice and a representative experiment is shown. In vivo tumorigenicity and drug treatment assays. All animal experiments were performed in accordance with a protocol approved by MSKCC Institutional Animal Care and Use Committee (#11-12-029). The size for each cohort was determined based on previous experience without specific statistical methods. We re-suspended 10 6 cells of stably transfected NIH-3T3 or melan-a cells in 50 ml of 1:1 mix of PBS and Matrigel (BD Biosciences), and subcutaneously and bilaterally injected the cells into the flanks of 6-8 weeks old female CB17-SCID mice (Taconic). Mice were chosen randomly and no animals were excluded. For tumour growth assays, 5 mice were injected with parental or stably transduced cell lines and 10 tumours were assessed (expect of melan-a cells stably transfected with ALK
F1174L
, in which 4 mice were injected and 8 tumours were assessed). Tumour sizes were measured with callipers, without blinding, every 2 to 7 days for a period of up to 100 days, and were calculated using the following formula: tumour volume 5 (D 3 d 2 )/2, whereby D and d refer to the long and short tumour diameter, respectively. For in vivo drug sensitivity studies, 9 mice were injected with the stably transduced NIH-3T3 cells expressing a luciferase reporter construct and the indicated plasmids. When the tumours reached an average size of 200-250 mm 3 , mice were randomized into a vehicle (4 mice) or treatment (5 mice) group. Mice were orally gavaged once a day with crizotinib (100 mg kg 21 per day) or vehicle. We performed non-blinded measurement of 8 tumours in the vehicle group and 10 tumours in the crizotinib group with callipers every 2 to 3 days, and growth curves were visualized with Prism GraphPad 6.0. In parallel, we monitored tumour growth by bioluminescence imaging of anaesthetized mice by retro-orbital injection of D-luciferin (150 mg per kg body weight) and imaging with the IVIS Spectrum Xenogen machine (Caliper Life Sciences). Bioluminescence analysis was performed using Living Image software, version 2.50. After euthanizing the mice, tumours were explanted and either lysed in RIPA buffer (Cell Signaling Technology) or fixed overnight in 4% paraformaldehyde, washed, embedded in paraffin, and sectioned for haematoxylin and eosin (H&E) staining or immunohistochemistry. Mice experiments were performed once. Table 2 shows the detected SNVs and indels at the ALK locus after filtering out SNPs documented in the dbSNP database. None of the genomic aberrations was found in more than one case, indicating that the expression of ALK ATI is probably not caused by alterations of the DNA nucleotide sequence. b, c, Circos plots of the whole-genome sequencing data of MM-15 (b) and ATC-28 (c) illustrating numerous SNV and structural aberrations. Supplementary Table 3 lists the  detected single nucleotide polymorphisms, and Supplementary Table 4 the detected structural aberrations. No recurrent genomic aberrations were found at the ALK locus. Extended Data Figure The frequency of ALK ATI -expressing tumours in more than 5,000 tumour samples from 15 different cancer types in the TCGA RNA-seq data set.
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